Arca
Skip to content
Tools
Tools

Label Changes: Sohonos (palovarotene)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Sohonos label DailyMed has published, from Ipsen Biopharmaceuticals, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 4
  • Sections changed, version 3 to 4: 3

What changed from version 3 to version 4

Aug 31, 2026 to Sep 28, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged ยท 29 words added, 1 removed
  2. Clinical pharmacologyChanged ยท 93 words added, 34 removed
  3. Patient counseling informationChanged ยท 71 words added, 33 removed

Dosage and administration

Changed29 words added, 1 removed
6 unchanged lines
Initiate flare-up treatment at the onset of the first symptom indicative of a FOP flare-up or substantial high-risk traumatic event likely to lead to a flare-up (e.g., surgery, intramuscular immunization, mandibular blocks for dental procedures, muscle fatigue, blunt muscle trauma from bumps, bruises, falls, or influenza-like viral illnesses). Symptoms of a FOP flare-up typically include but are not limited to localized pain, soft tissue swelling/inflammation, redness, warmth, decreased joint range of motion, and stiffness.
Multiple lower strength capsules (1 mg, 1.5 mg or 5 mg capsules) should not be substituted for a single 10 mg capsule [see Clinical Pharmacology (12.3)].
Recommended Dosage for Adults and Pediatric Patients 14 Years and Older
2 unchanged lines
Recommended Dosage for Pediatric Patients Aged 8 to 13 Years for Females and Aged 10 to 13 Years for Males
Daily Dose: The recommended SOHONOS daily dosage for patients under 14 years of age is weight-based, ranging from 2.5 mg to 5 mg daily (see Table 1). Stop daily dosing when flare-up dosing begins.
Flare-up Dose: The recommended flare-up SOHONOS dosage for patients under 14 years of age is weight-based (see Table 1). Administer the initial flare-up dosage once daily for 4 weeks, then administer the lower flare-up dosage once daily for 8 weeks (for a total of 12 weeks of flare-up treatment), even if symptoms resolve earlier, then return to daily dosing (see Table 1). If during the course of flare-up treatment, the patient experiences marked worsening of the original flare-up site or another flare-up at a new location, restart the 12-week flare-up dosing with the Week 1 to 4 dose. For flare-up symptoms that have not resolved at the end of the 12-week period, the Week 5 to 12 flare-up dose may be extended in 4-week intervals and continued until the flare-up symptoms resolve. If new flare-up symptoms occur after daily dosing is resumed, flare-up dosing may be restarted.
Table 1. Recommended SOHONOS Weight-Based Dosage for Pediatric Patients Aged 8 to 13 Years for Females and 10 to 13 Years for Males
Weight | Daily Dosage | Week 1 to 4 Flare-up Dosage | Week 5 to 12 Flare-up Dosage
10 kg to 19.9 kg | 2.5 mg | 10 mg | 5 mg
5 unchanged lines
2.3 Administration Instructions
Take SOHONOS with food, preferably at the same time each day. SOHONOS may be swallowed whole, or capsules may be opened and the contents emptied onto one teaspoon (5 mL) of soft food (such as apple sauce, low-fat yogurt, or warm oatmeal) and taken within 1 hour of opening provided it was maintained at room temperature and not exposed to direct sunlight [see Clinical Pharmacology (12.3)]. Do not administer SOHONOS with grapefruit, pomelo, or juices containing these fruits.
2.4 Dosage Reduction for Adverse Reactions
22 unchanged lines

Clinical pharmacology

Changed93 words added, 34 removed
6 unchanged lines
12.3 Pharmacokinetics
Palovarotene exposure (AUC) increases proportionally from 0.02 to 50 mg (0.001 to 2.5 times the maximum recommended dosage). Steady-state is achieved by Day 3 following once daily dosing. Palovarotene exposureexposures in patients with FOP are listed in Table 7.
Table 7. Palovarotene Exposures in Patients with FOP
5 unchanged lines
Absorption
The median time to achieve peak concentration (Tmax) of palovarotene was 3.0 to 4.0 hours across the chronic dose of 5 mg to flare-up dose of 10 and 20 mg.
The median time to achieve peak concentration (Tmax) of palovarotene was 3.0 to 4.0 hours across the chronic dose of 5 mg to flare-up dose of 10 and 20 mg. A study in 72 healthy subjects showed a 31% and 17% higher Cmax following four 2.5 mg capsules and two 5 mg capsules, respectively, compared to one 10 mg capsule. Therefore, multiple 1 mg, 1.5 mg, 2.5 mg, or 5 mg capsules are not substitutable for one 10 mg capsule [see Dosage and Administration (2.2)].
Effect of Food
28 unchanged lines

Patient counseling information

Changed71 words added, 33 removed
24 unchanged lines
Dosing Instructions:
Advise the patient to take SOHONOS capsules with food. If the patient is unable to swallow the capsule, the capsule contents may be emptied onto soft food [see Dosage and Administration (2.3)].
Advise the patient to take SOHONOS capsules with food. If the patient is unable to swallow the capsule, the capsule contents may be emptied onto soft food [see Dosage and Administration (2.3)]. Advise the patient that multiple lower strength capsules (1 mg, 1.5 mg and 5 mg capsules) should not be substituted for a single 10 mg capsule [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].
Missed dose:
1 unchanged line

Unchanged: Boxed warning, Indications and usage, Dosage forms and strengths, Contraindications, Warnings and precautions, Adverse reactions, Drug interactions, Use in specific populations, Overdosage, Description, Nonclinical toxicology, Clinical studies, How supplied, Untitled section, Medication guide, PRINCIPAL DISPLAY PANEL - 1 mg Capsule Blister Pack Carton, PRINCIPAL DISPLAY PANEL - 1.5 mg Capsule Blister Pack Carton, PRINCIPAL DISPLAY PANEL - 2.5 mg Capsule Blister Pack Carton, PRINCIPAL DISPLAY PANEL - 5 mg Capsule Blister Pack Carton, PRINCIPAL DISPLAY PANEL - 10 mg Capsule Blister Pack Carton.

Every version

4 versions of set 67dce406-7cc4-4d66-92de-ad18b6df0625, newest first.
VersionPublished on DailyMedCompareSPL file
4Sep 28, 2026Shown belowDownload .zip
3Aug 31, 2026With version 2Download .zip
2Mar 24, 2025With version 1Download .zip
1Aug 29, 2023First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.